NCT06748209 Establishing Mobile Transcranial Magnetic Stimulation
| NCT ID | NCT06748209 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Medical University of South Carolina |
| Condition | Treatment Resistant Major Depression |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-05-10 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 30 participants in total. It began in 2025-05-10 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this pilot study, investigators propose to design and create a portable TMS unit, in a van, and then test out delivering TMS in three different locations in South Carolina, all affiliated with MUSC and within 2-hours driving from Charleston, SC. This study would test out this new delivery mode, and provide valuable feasibility, safety, and efficacy lessons for later refinement and potential widespread adoption of mobile TMS as a treatment option, both in our state and across the US.
Eligibility Criteria
Inclusion Criteria: * Adult (22-80 years old) * Have treatment-resistant depression as defined by the e-Mini, and the antidepressant treatment history form (ATHF short). * Be able to read and communicate in English. * Able to provide their own consent. * Access to a computer with videoconferencing ability for initial consent and telescreen. Exclusion Criteria: * Patients with unstable medical conditions that might make TMS unsafe. This includes current poorly controlled seizures. * Ferromagnetic metal in the head. * Pregnant. * Currently active substance abuse except tobacco.
Contact & Investigator
Mark George, MD
PRINCIPAL INVESTIGATOR
Medical University of South Carolina
Frequently Asked Questions
Who can join the NCT06748209 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, up to 80 Years, studying Treatment Resistant Major Depression. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06748209 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06748209 currently recruiting?
Yes, NCT06748209 is actively recruiting participants. Contact the research team at GEORGEM@MUSC.EDU for enrollment information.
Where is the NCT06748209 trial being conducted?
This trial is being conducted at Charleston, United States.
Who is sponsoring the NCT06748209 clinical trial?
NCT06748209 is sponsored by Medical University of South Carolina. The principal investigator is Mark George, MD at Medical University of South Carolina. The trial plans to enroll 30 participants.
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.